Back to Top Skip to main content Skip to sub-navigation

Investigational New Drug

Date of Publication



A drug or biological product subject to the FDA regulations at Part 312 of Title 21, Code of Federal Regulations, Parts 50, 56, 312, Subpart I of Part 314, Subpart G  of Part 601, as amended, including: A drug not approved or a biological product not licensed by the FDA and a drug unapproved for its applied use.

Source of Definition

DoD Instruction 6200.02: Application of FDA Rules to Department of Defense Force Health Protection Programs

Related Glossary Terms

Investigational New Drug

Last Updated: August 01, 2022

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.